Haematological complications of therapy with pyrimidine analogues

C. G. GEARY

Department of Haematology, United Manchester Hospitals, Manchester M13 9WL

Pyrimidine analogues produce their effects by inhibiting nucleic acid synthesis and inevitably damage tissues with high rates of cell turnover. These are the bone marrow, gastro-intestinal epithelium, and, to a lesser extent, renal and hepatic parenchyma and skin. The haematologist who treats a case of acute leukaemia with cytosine arabinoside is, of course, attempting ablation of the leukaemic marrow; the rationale of this therapy presupposes the existence of residual normal haemopoietic stem cells, which are capable of repopulating the marrow (Killmann, 1970). In this situation moderate or severe hypoplasia of the bone marrow is an inevitable prelude to remission of the disease (Bailey et al., 1971).

In the treatment of viral infections with pyrimidine analogues, on the other hand, the haematological side-effects are incidental though none the less hazardous. However, the functional reserve of normal marrow is considerable. Haemopoietic cell-lines can be considered divided into three compartments: stem cells, maturing (‘committed’) cells, and functional cells (Fig. 1). Proliferation occurs, albeit slowly, in the stem-cell compartment, which has the dual role of self-maintenance and of providing cells for the maturation pathway: their numbers and proliferation rates are under homeostatic control. Proliferation is also occurring amongst the earlier members of the maturing cell compartment. In the normal marrow, events in this compartment dominate the proliferative characteristics of the tissue (Lamerton & Steel, 1968; Lamerton, 1972).

It has been demonstrated in experimental animals that stem cells account for only about 1%, or less, of the proliferating cells present in the marrow; the remainder are in the maturing compartment, which are also dividing much more rapidly (Lahiri & van Putten, 1969). The rate of production of mature erythrocytes, granulocytes and platelets depends on the intermitotic time of the dividing cells; in the maturing compartment this is probably a matter of hours, whereas in the stem-cell compartment, divisions occur much less frequently. Thus, in the marrow, there is a small, normally slowly dividing stem-cell compartment and a much larger and rapidly-dividing population of later committed precursors.

The capacity of the marrow to withstand damage by cytotoxic drugs depends on two critical factors: (1) the speed with which the stem-cell population can regenerate following death of more mature cells and (2) the number of stem cells required.

Pyrimidine analogues are ‘phase-specific’ drugs, that is, they act only on replicating cells during the S-phase of the cycle. They appear to have no effect on stem cells, or on ‘resting cells’ (in G0). Since the dividing cells are not in synchrony, but are entering S-phase at different times, it has been held that the cytotoxic action of these drugs is enhanced if given as a slow continuous infusion: there is some support from haematological practice that this is so (Ellison et al., 1968).

In rats, it has been shown that, following obliteration of all recognizable granulocyte and erythroblast precursor cells with methotrexate, the stem-cell population re-establishes haemopoietic function so rapidly that red cell and granulocyte production are back to 50% of their normal values 3½ and 6 days, respectively, after the production of aplasia (Blackett, 1968). In man, regeneration is slower, but it is important to realize that in aplasia produced by pyrimidine analogues, recovery can be expected if the patient has normal marrow reserve and can be protected during the aplastic phase. The situation is thus different from that in idiopathic aplasia, or that...
due to some drugs, in which concomitant damage to the microvasculature of the marrow, possibly mediated by an immunological mechanism, delays or prevents recovery. On the other hand, patients with reduced marrow function may suffer prolonged hypoplasia. These include the elderly, those with malignant haematological disorders, hepatic or renal disease, overwhelming toxaemia or previous malnutrition.

**Therapy with IDU and Ara-C**

There are now a number of reports of treatment of viral infections with systemic pyrimidine analogues. Haematological side-effects have been variable and apparently unpredictable: thus Nolan and his colleagues reported troublesome leucopenia and thrombocytopenia after the use of IDU (Nolan, Carruthers & Lever, 1970). On the other hand, Juel-Jensen (1971) treated five cases of disseminated herpetic infection with Ara-C at a dosage of 2 mg/kg body weight without any signs of marrow depression, and Longson reported no haematological side-effects in patients treated with IDU at a dosage of 100 mg/kg body weight.

**Table 1. Side-effects of IDU and Ara-C**

<table>
<thead>
<tr>
<th>IDU</th>
<th>Ara-C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancytopenia</td>
<td>Megaloblastosis</td>
</tr>
<tr>
<td>Aplastic anaemia</td>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>Pancytopenia</td>
</tr>
<tr>
<td>Enteritis</td>
<td>Aplastic anaemia</td>
</tr>
<tr>
<td>Alopecia</td>
<td>Immunosuppression</td>
</tr>
<tr>
<td>Nail loss</td>
<td>Gastro-intestinal disturbance</td>
</tr>
<tr>
<td>Chromosomal changes (?)</td>
<td>Renal and hepatic damage</td>
</tr>
<tr>
<td></td>
<td>Fever</td>
</tr>
<tr>
<td></td>
<td>Rash</td>
</tr>
<tr>
<td></td>
<td>Chromosomal changes (?)</td>
</tr>
</tbody>
</table>

Figures 2 and 3 represent the haematological progress of two haematologically normal patients treated, respectively, with Ara-C and IDU. The onset of marrow depression is not usually noted until about the seventh day; it is usual to give pyrimidine analogues in ‘pulses’ over 3–5 days, and the pancytopenia may not appear until after the drug has been withdrawn. Thrombocytopenia is often the first sign of marrow damage, though examination of the marrow will show toxic changes much earlier; for example striking megaloblastosis is a feature of treatment with Ara-C, and develops within hours. Marrow aspiration later will show hypoplasia or aplasia; thus in the patient illustrated in Fig. 1, the marrow was completely aplastic at Day 14. The extent of myeloid depression is best assessed by marrow aspiration; the peripheral blood count may be misleading.

Calabresi (1965) attempted regional protection of femoral marrow in patients with malignant disorders undergoing treatment of viral infections with IDU; intra-arterial infusions of thymidine appeared to preserve some haemopoietic function in this site. It is interesting that second courses of the analogue seem to cause less marrow depression than the first (Fig. 2).

**The hypoplastic phase**

Once severe marrow hypoplasia is established, therapy with the analogue must be stopped. Withdrawal of the drug may be sufficient, but a prolonged aplastic episode is a serious complication, even though eventual marrow recovery can be expected.
Complications with pyrimidine analogues

415

The risks are of thrombocytopenic bleeding, particularly cerebral haemorrhage, and septicaemia. Serious haemorrhage is rarely a risk with a platelet count of more than 20,000/mm³ (Editorial, 1972). When haemorrhage occurs it is best treated by fresh blood and, if possible, platelet transfusions. Six platelet concentrates are given, repeated 12 hr later if no clinical response is evident. Improvement may be monitored by the platelet count and bleeding time. Infection often exacerabtes thrombocytopenic bleeding and requires vigorous treatment. A neutrophil count of less than 250/mm³ for more than 2 or 3 days is an ominous sign; Gram-negative septicaemia and secondary fungal infections are definite risks. Blood cultures, naso-pharyngeal, sputum, urine and perineal swabs should be taken, and the patient barrier-nursed in a side ward. In patients with profound neutropenia, Gram-negative septicaemia is probably best treated with a combination of intravenous carbenicillin and cephaloridine; gentamicin seems to be less effective in the absence of functioning granulocytes.

A bowel sterilization programme, using broad-spectrum antibiotics and an anti-fungal agent, has been advocated in patients with agranulocytosis; early reports suggest that this regimen is more effective if the patient is isolated in a plastic 'life-island' or a laminar air flow system (van der Weyden & Firkin, 1972). Leucocyte infusions are now a practical proposition in centres where IBM cell separators are available, and may be of value in the presence of septicaemia or infections not responsive to antibiotics.

Anaemia will eventually occur if the aplasia is prolonged or if accompanied by thrombocytopenic bleeding; it is best treated by packed cells or fresh blood if there is profound thrombocytopenia.

Steroid therapy

Prednisolone is often given to patients with amegakaryocytic thrombocytopenia but it is of doubtful value; in patients with severe neutropenia, it may increase the risks of infection and would possibly be undesirable in patients with disseminated viral infections. The androgen derivative, oxymethalone, is however, effective in approximately 50% of cases of aplastic anaemia, and should be administered in any case in which aplasia is prolonged (Sanchez-Medal et al., 1969). It appears to be more effective in stimulating erythropoiesis than leucopoiesis or thrombopoiesis, but the clinical manifestations of bleeding usually disappear in those patients responding to the drug.

References


LONGSON, M. Personal communication.


Haematological complications of therapy with pyrimidine analogues
C. G. Geary

Postgrad Med J 1973 49: 413-415
doi: 10.1136/pgmj.49.572.413